ALK and neuroblastoma: It has single-agent antitumor activity in neuroblastoma xenografts that express the three most common ALK mutations – F1174L, R1275Q and F1245C (Infarinato et al., 2016), providing the rationale to test more potent ALK inhibitors in clinic.